ALIM Alimera Sciences Inc.

3.62
-0.38  -10%
Previous Close 4
Open 4.21
Price To Book -0.52
Market Cap 17,976,735
Shares 4,965,949
Volume 19,242
Short Ratio
Av. Daily Volume 37,954
Stock charts supplied by TradingView

NewsSee all news

  1. Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

    ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,

  2. Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

    ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management

  3. Alimera Sciences Reports Record Fourth Quarter and 2019 Results

    Fourth Quarter Highlights: Consolidated Net Revenue of $17.3 Million; Up 15% Over Q4 2018International Net Revenue Up 26% Compared to Q4 2018Net Income of $498,000 vs. Net Loss of $1.2 million in Q4 2018$2.6 million

  4. Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement

    ATLANTA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  5. Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update

    ATLANTA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

    ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,

  2. Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

    ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management

  3. Alimera Sciences Reports Record Fourth Quarter and 2019 Results

    Fourth Quarter Highlights: Consolidated Net Revenue of $17.3 Million; Up 15% Over Q4 2018International Net Revenue Up 26% Compared to Q4 2018Net Income of $498,000 vs. Net Loss of $1.2 million in Q4 2018$2.6 million

  4. Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement

    ATLANTA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  5. Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update

    ATLANTA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  6. Alimera Sciences, Inc 13D/A filing

    CHICAGO, Jan. 27, 2020 /PRNewswire/ -- Private investor, Ronald Chez, increases Alimera position. Media contact: Elias Matsakis, Holland & Knight LLP View original

  7. Alimera Sciences Refinances Its Debt Facility With Solar Capital

    Three-year interest-only periodAdditional $2.5 million available under certain conditions ATLANTA, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization

  8. Almira Sciences, Inc 13D filing

    CHICAGO, Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ:ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th

  9. Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

    ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  10. Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

    Company continues to execute on its international expansion strategy ATLANTA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of

  11. Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  12. Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

    ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  13. Alimera Sciences Terminates Equity Purchase Agreement

    ATLANTA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  14. Alimera Sciences Announces Board's Approval of Reverse Stock Split Ratio

    ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  15. Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

    ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  16. Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018International Net Revenue Up 62% Compared to Third Quarter 2018Launch of ILUVIEN® for Non-Infectious Posterior

  17. Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    ATLANTA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  18. Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    ATLANTA, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  19. Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  20. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    ATLANTA, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  21. Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  22. Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal